159 related articles for article (PubMed ID: 38434237)
1. Metastatic Kidney Cancer: Does the Location of the Metastases Matter? Moving towards Personalized Therapy for Metastatic Renal Cell Carcinoma.
Baston C; Parosanu AI; Stanciu IM; Nitipir C
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791072
[TBL] [Abstract][Full Text] [Related]
2. The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma.
Naik P; Dudipala H; Chen YW; Rose B; Bagrodia A; McKay RR
Ther Adv Urol; 2024; 16():17562872241232578. PubMed ID: 38434237
[TBL] [Abstract][Full Text] [Related]
3. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
4. The role of immunotherapy in non-clear cell renal cell carcinoma.
Climent C; Soriano S; Bonfill T; Lopez N; Rodriguez M; Sierra M; Andreu P; Fragio M; Busquets M; Carrasco A; Cano O; Seguí MA; Gallardo E
Front Oncol; 2023; 13():941835. PubMed ID: 36816976
[TBL] [Abstract][Full Text] [Related]
5. Systemic Therapies for the Management of Non-Clear Cell Renal Cell Carcinoma: What Works, What Doesn't, and What the Future Holds.
Zoumpourlis P; Genovese G; Tannir NM; Msaouel P
Clin Genitourin Cancer; 2021 Apr; 19(2):103-116. PubMed ID: 33358151
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
7. Systemic Treatment for Advanced and Metastatic Non-Clear Cell Renal Cell Carcinoma: Examining Modern Therapeutic Strategies for a Notoriously Challenging Malignancy.
Drobner J; Portal D; Runcie K; Yang Y; Singer EA
J Kidney Cancer VHL; 2023; 10(3):37-60. PubMed ID: 37789902
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L; Gurney H; Atduev V; Suarez C; Climent MA; Pook D; Tomczak P; Barthelemy P; Lee JL; Stus V; Ferguson T; Wiechno P; Gokmen E; Lacombe L; Gedye C; Perini RF; Sharma M; Peng X; Lee CH
Lancet Oncol; 2023 Aug; 24(8):881-891. PubMed ID: 37451291
[TBL] [Abstract][Full Text] [Related]
9. Renal Cell Carcinoma of Variant Histology: Biology and Therapies.
Msaouel P; Genovese G; Tannir NM
Hematol Oncol Clin North Am; 2023 Oct; 37(5):977-992. PubMed ID: 37244822
[TBL] [Abstract][Full Text] [Related]
10. SMARCB1 regulates a TFCP2L1-MYC transcriptional switch promoting renal medullary carcinoma transformation and ferroptosis resistance.
Vokshi BH; Davidson G; Tawanaie Pour Sedehi N; Helleux A; Rippinger M; Haller AR; Gantzer J; Thouvenin J; Baltzinger P; Bouarich R; Manriquez V; Zaidi S; Rao P; Msaouel P; Su X; Lang H; Tricard T; Lindner V; Surdez D; Kurtz JE; Bourdeaut F; Tannir NM; Davidson I; Malouf GG
Nat Commun; 2023 May; 14(1):3034. PubMed ID: 37236926
[TBL] [Abstract][Full Text] [Related]
11. Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.
Rizzo M; Caliò A; Brunelli M; Pezzicoli G; Ganini C; Martignoni G; Camillo P
Cancer Treat Rev; 2023 May; 116():102558. PubMed ID: 37060647
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B).
Atkins MB; Jegede OA; Haas NB; McDermott DF; Bilen MA; Stein M; Sosman JA; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Signoretti S; Denize T; Cimadamore A; Wu CJ; Braun D; Einstein D; Catalano PJ; Hammers H
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36948504
[TBL] [Abstract][Full Text] [Related]
13. Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
Suárez C; Larkin JMG; Patel P; Valderrama BP; Rodriguez-Vida A; Glen H; Thistlethwaite F; Ralph C; Srinivasan G; Mendez-Vidal MJ; Hartmaier R; Markovets A; Prendergast A; Szabados B; Mousa K; Powles T
J Clin Oncol; 2023 May; 41(14):2493-2502. PubMed ID: 36809050
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
